High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by a three-year rituximab maintenance
José A. García-Marco, Javier López Jiménez, Valle Recasens, Miguel Fernández Zarzoso, Eva González-Barca, Nieves Somolinos De Marcos, M. Jose Ramírez, Francisco Javier Peñalver Parraga, Lucrecia Yañez, Javier De La Serna Torroba, Maria Dolores Garcia Malo, Guillermo Deben Ariznavarreta, Ernesto Perez Persona, M. Angeles Ruiz Guinaldo, Raquel De Paz Arias, Elena Bañas Llanos, Isidro Jarque, M. del Carmen Fernandez Valle, Ana Carral Tatay, Jaime Perez De Oteyza, Eva Donato Martin, Inmaculada Perez Fernández, Rafael Martinez Martinez, M. Angeles Andreu Costa, Diana Champ, Julio García Suarez, Marcos González Diaz, Secundino Ferrer, Félix Carbonell, José A. García-Vela, GELLC (Grupo Español de Leucemia Linfocítica Crónica) Study Group
Haematologica Mar 2019, haematol.2018.204891; DOI: 10.3324/haematol.2018.204891
